ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners

7/23/24 8:38:05 AM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $CDXC alert in real time by email

Results from the at-home test kit are available to HCPs and their patients through 1health

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company's healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boosting HCP products, Tru Niagen® and Niagen+.

Get the next $CDXC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CDXC

Date	Price Target	Rating	Analyst
8/16/2022		Outperform → Perform	Oppenheimer
8/11/2022	$6.00 → $2.40	Buy → Neutral	B. Riley Securities
3/10/2022	$16.00 → $8.00	Buy	B. Riley Securities
3/8/2022	$7.00	Buy	ROTH Capital
8/4/2021	$11.00 → $12.00	Buy	HC Wainwright & Co.

More analyst ratings

$CDXC
Press Releases

Fastest customizable press release news feed in the world

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology's inaugural supplement called Longevity.Technology® LONGEVITY. Designed to support a healthier, longer life, the supplement includes Niagen, the gold standard ingredient for enhancing NAD+ levels and optimizing cellular health. Longevity.Technology,
11/14/24 8:32:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan. Available in oral and IV
11/7/24 8:32:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi
10/31/24 4:04:00 PM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care

$CDXC
Financials

Live finance-specific insights

ChromaDex Corporation Reports Third Quarter 2024 Financial Results
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi
10/31/24 4:04:00 PM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Thursday, October 31, 2024, at 4:30 p.m.
10/28/24 8:32:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Wednesday, November 6, at 4:30 p.m. ET. Participants should call in
10/24/24 8:32:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care

$CDXC
Leadership Updates

Live Leadership Updates

ChromaDex Appoints Ozan Pamir as Chief Financial Officer
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Mr. Fried commented, "We are very pleased to welcome Ozan to the ChromaDex team. His ambitious work ethic and impressive professional background will help us to embark on this critical next phase of develo
9/20/24 8:32:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Carlos Lopez is a distinguished legal professional and executive leader with expertise in the dietary supplements industry. Prior to joining ChromaDex, he served as the Vice President, General Counsel at The Vitamin Sh
7/22/24 8:34:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care
ChromaDex to Join Russell 2000® Index
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, "Joining the Russel
7/1/24 8:32:00 AM ET
$CDXC
Medicinal Chemicals and Botanical Products
Health Care

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners

Chat with this insight

Recent Analyst Ratings for $CDXC

$CDXC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gerber Brianna bought $7,050 worth of shares (5,000 units at $1.41), increasing direct ownership by 22% to 27,436 units (SEC Form 4)

$CDXC Press Releases

Fastest customizable press release news feed in the world

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

$CDXC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Lopez Carlos Luis claimed ownership of 1,978 shares (SEC Form 3)

SEC Form 4 filed by Chief Financial Officer Pamir Ozan

SEC Form 3 filed by new insider Pamir Ozan

$CDXC SEC Filings

SEC Form 424B3 filed by ChromaDex Corporation

ChromaDex Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$CDXC Financials

Live finance-specific insights

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

$CDXC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

SEC Form SC 13D/A filed by ChromaDex Corporation (Amendment)

$CDXC Leadership Updates

Live Leadership Updates

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex to Join Russell 2000® Index

$CDXC Market Insights

Live Market Insights

$CDXC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.